{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062042","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.012348+00:00","generated_at":"2026-06-08T06:57:32.930113+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Enliven Therapeutics Q3 net loss $20.8M; cash $263.5M; ELVN-001/002 data on track for 2024","bullets":["Cash, cash equivalents and marketable securities of $263.5M as of Sept 30, 2023; expected runway into early 2026.","Net loss $20.8M vs $10.6M in Q3 2022; R&D expense $19.6M (up from $7.8M); G&A $4.6M (up from $3.1M).","ELVN-001 (CML) and ELVN-002 (HER2-altered solid tumors) Phase 1 trials enrolling; initial proof-of-concept data expected in 2024.","Third IND-enabling study completed; additional pipeline details and guidance planned for H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062042","json":"https://secwatch.observer/filing/0000950170-23-062042.json","markdown":"https://secwatch.observer/filing/0000950170-23-062042.md","text":"https://secwatch.observer/filing/0000950170-23-062042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000095017023062042/0000950170-23-062042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000095017023062042/elvn-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:57:32.930113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"237abf952c4b56b1440774f4b6cf9fe6b32f4257","claim":"Enliven Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $20.8 million.","evidence_excerpt":"Enliven reported a net loss of $20.8 million for the third quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672619/000095017023062042/0000950170-23-062042-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"$20.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}